1336955-89-5

Basic information

• Product Name: 3-broMo-5h-cyclopenta[b]pyridin-7(6h)-one
• Synonyms: 3-broMo-5h-cyclopenta[b]pyridin-7(6h)-one;3-bromo-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one;3-bromo-5,6-dihydrocyclopenta[b]pyridin-7-one
• CAS NO: 1336955-89-5
• Molecular Formula: C₈H₆BrNO
• Molecular Weight: 212.04334
• Mol File: 1336955-89-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 322.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.704±0.06 g/cm3(Predicted)
• PKA: 1.14±0.20(Predicted)
• CAS DataBase Reference: 3-broMo-5h-cyclopenta[b]pyridin-7(6h)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-broMo-5h-cyclopenta[b]pyridin-7(6h)-one(1336955-89-5)
• EPA Substance Registry System: 3-broMo-5h-cyclopenta[b]pyridin-7(6h)-one(1336955-89-5)

Safety Data

• Hazardous Substances Data: 1336955-89-5(Hazardous Substances Data)

Upstream product

• 533-37-9 2,3-cyclopentenopyridine 
• 1379342-51-4 3-bromo-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol 
• 158331-18-1 3-bromo-6,7-dihydro-5H-cyclopenta[b]pyridine 

Downstream Products

• 1379342-51-4 3-bromo-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol 

Relevant articles and documents

Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors

p300 and CREB-binding protein (CBP) are ubiquitously expressed pleiotropic lysine acetyltransferases and play a key role as transcriptional co-Activators that are essential for a multitude of cellular processes. Despite great importance, there is a lack of highly selective, potent, druglike p300/CBP inhibitors. Through the artificial-intelligence-Assisted drug discovery pipeline and further optimization, we reported the discovery of novel, highly selective, potent small-molecule inhibitors of p300/CBP histone acetyltransferases (HAT) with desired druglike properties, exemplified by B026. Our data demonstrated that B026, with half maximal inhibitory concentration (IC50) values of 1.8 nM to p300 and 9.5 nM to CBP enzyme inhibitory activity, is the most potent, selective p300/CBP HAT inhibitor. Moreover, B026 achieves significant and dose-dependent tumor growth inhibition in an animal model of human cancer, suggesting that B026 is a highly promising p300/CBP HAT inhibitor and warrants extensive preclinical investigation as a potential clinical development candidate.

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

ANTIDIABETIC BICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-co